NFKB1 and neuroblastoma: These data lend further support to a model in which intrinsically activated, p50‐deficient myeloid cells induce antitumor T‐cell immunity and demonstrate the feasibility of impeding HR Nb tumor growth with adoptively transferred p50‐IMC generated from WT marrow by gene editing.